Tarsus Pharmaceuticals, Inc

Contributing Author

Recent Articles by Tarsus Pharmaceuticals, Inc

Oct-29	Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026 TARS GlobeNewswire
Oct-28	Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer TARS GlobeNewswire
Sep-29	Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting TARS GlobeNewswire
Sep-04	Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care TARS +9.10% GlobeNewswire
Sep-01	Tarsus to Participate in Upcoming Investor Conferences TARS TARS +11.76% GlobeNewswire
Aug-06	Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth TARS +6.59% GlobeNewswire
Aug-06	Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing TARS +6.59% GlobeNewswire
Aug-06	Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position TARS +6.59% GlobeNewswire
Aug-05	Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 TARS +6.59% GlobeNewswire
Jul-13	Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth TARS TARS -5.40% GlobeNewswire
Jul-08	Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101 TARS TARS -5.30% GlobeNewswire
May-28	Tarsus to Participate in Upcoming Investor Conferences TARS GlobeNewswire
May-14	Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans TARS GlobeNewswire
May-07	Tarsus to Participate in Upcoming Investor Conferences TARS GlobeNewswire
Apr-29	Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026 TARS GlobeNewswire
Mar-31	Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease TARS GlobeNewswire
Mar-23	TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus TARS GlobeNewswire
Feb-26	Tarsus to Participate in Upcoming Investor Conferences TARS GlobeNewswire
Feb-23	Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements TARS TARS +7.79% GlobeNewswire
Feb-18	Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors TARS GlobeNewswire
Feb-17	Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026 TARS GlobeNewswire
Nov-24	Tarsus to Participate in Upcoming Investor Conference TARS GlobeNewswire
Nov-05	Tarsus to Participate in Upcoming Investor Conference TARS GlobeNewswire
Nov-04	Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements TARS GlobeNewswire
Oct-28	Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 TARS GlobeNewswire
Aug-27	Tarsus to Participate in Upcoming Investor Conferences TARS GlobeNewswire
Aug-06	Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements TARS TARS +15.15% GlobeNewswire
Jul-30	Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 TARS GlobeNewswire
May-29	Tarsus to Participate in Upcoming Investor Conferences TARS GlobeNewswire
May-08	Tarsus to Participate in Upcoming Investor Conferences TARS TARS -5.05% GlobeNewswire
May-01	Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements TARS TARS -5.84% GlobeNewswire

Tarsus Pharmaceuticals, Inc

Recent Articles by Tarsus Pharmaceuticals, Inc

Upgrade your Finviz experience